

Giuseppe Scaletta

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3063953/publications.pdf>

Version: 2024-02-01

38
papers

791
citations

516710

16
h-index

526287

27
g-index

38
all docs

38
docs citations

38
times ranked

1137
citing authors

#	ARTICLE	IF	CITATIONS
1	The role of novel biomarker HE4 in the diagnosis, prognosis and follow-up of ovarian cancer: a systematic review. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 827-839.	2.4	111
2	A new type of absorbable barbed suture for use in laparoscopic myomectomy. <i>International Journal of Gynecology and Obstetrics</i> , 2012, 117, 220-223.	2.3	65
3	Does HE4 have a role as biomarker in the recurrence of ovarian cancer?. <i>Tumor Biology</i> , 2012, 33, 2117-2123.	1.8	54
4	Ten years of HPV vaccines: State of art and controversies. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 102, 65-72.	4.4	52
5	Ovarian cancer recurrence and early detection: may HE4 play a key role in this open challenge? A systematic review of literature. <i>Medical Oncology</i> , 2017, 34, 164.	2.5	51
6	Utility of tumor marker HE4 as prognostic factor in endometrial cancer: a single-center controlled study. <i>Tumor Biology</i> , 2015, 36, 4151-4156.	1.8	37
7	The role of HE4 in endometrial cancer recurrence: how to choose the optimal follow-up program. <i>Tumor Biology</i> , 2016, 37, 4973-4978.	1.8	33
8	Assessment of Quality of Life and Urinary and Sexual Function After Radical Hysterectomy in Long-Term Cervical Cancer Survivors. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 818-823.	2.5	31
9	Ovarian cancer relapse: From the latest scientific evidence to the best practice. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 140, 28-38.	4.4	31
10	Preoperative local staging of endometrial cancer: the challenge of imaging techniques and serum biomarkers. <i>Archives of Gynecology and Obstetrics</i> , 2016, 294, 1291-1298.	1.7	25
11	Hormone replacement therapy in cancer survivors: Utopia?. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 124, 51-60.	4.4	22
12	Further insight into prognostic factors in endometrial cancer: the new serum biomarker HE4. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 9-18.	2.4	21
13	Quality of Life in Platinum-Sensitive Recurrent Ovarian Cancer: Chemotherapy Versus Surgery Plus Chemotherapy. <i>Annals of Surgical Oncology</i> , 2015, 22, 2387-2394.	1.5	20
14	A Predictive Score for Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer (SeC-Score): A Single-Centre, Controlled Study for Preoperative Patient Selection. <i>Annals of Surgical Oncology</i> , 2015, 22, 4217-4223.	1.5	20
15	Role of paroxetine in the management of hot flashes in gynecological cancer survivors: Results of the first randomized single-center controlled trial. <i>Gynecologic Oncology</i> , 2016, 143, 584-588.	1.4	20
16	Sarcopenia in Ovarian Cancer Patients, Oncologic Outcomes Revealing the Importance of Clinical Nutrition: Review of Literature. <i>Current Pharmaceutical Design</i> , 2019, 25, 2480-2490.	1.9	19
17	A randomized controlled trial comparing four versus six courses of adjuvant platinum-based chemotherapy in locally advanced cervical cancer patients previously treated with neo-adjuvant chemotherapy plus radical surgery. <i>Gynecologic Oncology</i> , 2015, 139, 433-438.	1.4	16
18	The Role of HE4, a Novel Biomarker, in Predicting Optimal Cytoreduction After Neoadjuvant Chemotherapy in Advanced Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 696-702.	2.5	16

#	ARTICLE	IF	CITATIONS
19	Role of human epididymis protein 4 (HE4) in detecting recurrence in CA125 negative ovarian cancer patients. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 768-771.	2.5	16
20	The use of novel hemostatic sealant (Tisseel®) in laparoscopic myomectomy: a caseâ€“control study. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2012, 26, 2046-2053.	2.4	14
21	Patients treated with neoadjuvant chemotherapy+radical surgery+adjuvant chemotherapy in locally advanced cervical cancer: long-term outcomes, survival and prognostic factors in a single-center 10-year follow-up. <i>Medical Oncology</i> , 2016, 33, 110.	2.5	14
22	Antiangiogenics and immunotherapies in cervical cancer: an update and futureâ€™s view. <i>Medical Oncology</i> , 2017, 34, 115.	2.5	14
23	Preeclampsia and the challenge of early prediction: reality or utopia? State of art and critical review of literature. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2020, 33, 677-686.	1.5	12
24	Adjuvant chemotherapy after primary treatments for cervical cancer: a critical point of view and review of the literature. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 431-439.	2.4	11
25	Validation of REM score to predict endometrial cancer in patients with ultrasound endometrial abnormalities: results of a new independent dataset. <i>Medical Oncology</i> , 2017, 34, 82.	2.5	11
26	Management of postoperative chylous ascites after surgery for ovarian cancer: a single-institution experience. <i>Updates in Surgery</i> , 2019, 71, 729-734.	2.0	11
27	Chemotherapy as Adjuvant Treatment for Intermediate-High Risk Early-Stage Endometrial Cancer. <i>International Journal of Gynecological Cancer</i> , 2015, 25, 1418-1423.	2.5	7
28	The impact of gynecologic oncology training in the management of cancer patients: is it really necessary? A prospective cohort study. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2015, 184, 19-23.	1.1	7
29	Implementing the Risk of Endometrial Malignancy Algorithm (REM) adding obesity as a predictive factor: Results of REM-B in a single-center survey. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2018, 225, 51-56.	1.1	6
30	Assessing HPV vaccination perceptions with online social media in Italy. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 453-458.	2.5	6
31	Long-term follow-up of bulking agents for stress urinary incontinence in older patients. <i>Menopause</i> , 2018, 25, 663-667.	2.0	5
32	The role of human epididymis protein 4 as a biomarker in gynecologic malignancies. <i>Minerva Ginecologica</i> , 2019, 71, 36-43.	0.8	4
33	Primary chemotherapy versus primary surgery for ovarian cancer. <i>Lancet, The</i> , 2015, 386, 2142.	13.7	2
34	The role of macroplastique implantation in the management of occult urinary stress incontinence. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2018, 225, 124-128.	1.1	2
35	Undescended or absent ovary without uterine anomalies: systematic review and a single center's experience. <i>Minerva Obstetrics and Gynecology</i> , 2017, 69, 35-40.	1.0	2
36	Real-time infrared thermography for ureter detection during hysterectomy. <i>Journal of Surgical Research</i> , 2012, 178, 539-544.	1.6	1

#	ARTICLE	IF	CITATIONS
37	Anterior colporrhaphy plus inside-out tension-free vaginal tape for associated stress urinary incontinence and cystocele: 10-year follow up results. <i>Neurourology and Urodynamics</i> , 2018, 37, 1144-1151.	1.5	1
38	Update on new imaging technologies in sentinel node detection. <i>Minerva Ginecologica</i> , 2021, 72, 404-412.	0.8	1